<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677014</url>
  </required_header>
  <id_info>
    <org_study_id>CR-CA-050508-H</org_study_id>
    <nct_id>NCT00677014</nct_id>
  </id_info>
  <brief_title>Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)</brief_title>
  <acronym>SMART-AV</acronym>
  <official_title>SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of SMART-AV is to assess the effect of SmartDelay for determining
      optimal AV delay timing during CRT compared to both a fixed AV delay and
      echocardiography-determined optimal AV timing chronically over a 6-month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SMART-AV is a randomized, multi-center, double-blinded, non-significant risk, three-armed
      trial that will investigate the effects of optimizing AV delay timing in heart failure
      patients receiving CRT-D therapy. Patients will be randomized in a 1:1:1 ratio using randomly
      permuted blocks within each center. The study will compare chronic changes in structural and
      functional outcomes in CRT-D patients randomized to AV delay set as fixed, set with
      SmartDelay or determined by echocardiography. Patients will be followed at enrollment,
      implant, post-implant, 3-months post-implant and 6-months post-implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular End-systolic Volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in square root of absolute left ventricular end systolic volume from baseline to 6 month follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints Will Include Structural and Functional Measures</measure>
    <time_frame>Chronic</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1060</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Echo optimized AV delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Echo optimized AV delay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Algorithm optimized AV delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Algorithm optimized AV delay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed AV Delay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed AV Delay</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV Delay programming through cardiac resynchronization therapy</intervention_name>
    <description>All subjects in this trial receive the same device. For the purpose of this trial. &quot;intervention&quot; is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.</description>
    <arm_group_label>Fixed AV Delay</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV Delay programming through cardiac resynchronization therapy</intervention_name>
    <description>All subjects in this trial receive the same device. For the purpose of this trial. &quot;intervention&quot; is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.</description>
    <arm_group_label>Algorithm optimized AV delay</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV Delay programming through cardiac resynchronization therapy</intervention_name>
    <description>All subjects in this trial receive the same device. For the purpose of this trial. &quot;intervention&quot; is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.</description>
    <arm_group_label>Echo optimized AV delay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet current indications for a BSC CRT-D device with the SmartDelay
             algorithm

          -  Patients who are willing and capable of undergoing a device implant and participating
             in all testing associated with the SMART-AV Study

          -  Patients who are on optimal and stable pharmacologic therapy

          -  Patients who are expected to be in sinus rhythm at the time of implant

          -  Patients who have a life expectancy of more than 360 days, per physician's discretion

          -  Patients who are geographically stable and willing to comply with the required
             follow-up schedule

          -  Patients who are 18 years of age or above, or of legal age to give informed consent
             specific to state and national law

        Exclusion Criteria:

          -  Patients who are in complete heart block, or who otherwise are unable to tolerate
             pacing at VVI-40 RV for up to 14 days

          -  Patients undergoing an upgrade of a pacemaker or implantable
             cardioverter-defibrillator who are unable to tolerate pacing at VVI-40 RV for up to 14
             days

          -  Patients who have previously received cardiac resynchronization therapy

          -  Patients who are expected to receive a heart transplant or have other cardiac
             surgeries or procedures planned during the course of the study

          -  Patients who currently have or who are likely to receive a tricuspid valve prosthesis

          -  Patients who have a neuromuscular, orthopedic, or other non-cardiac condition that
             prevents normal, unsupported walking

          -  Patients who are pregnant or planning to become pregnant during the study

          -  Patients who are currently enrolled in another investigational study or registry that
             would directly impact the treatment or outcome of the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CRM Clinical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bostonscientific.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation. 1999 Jun 15;99(23):2993-3001.</citation>
    <PMID>10368116</PMID>
  </reference>
  <reference>
    <citation>Auricchio A, Ding J, Spinelli JC, Kramer AP, Salo RW, Hoersch W, KenKnight BH, Klein HU. Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. J Am Coll Cardiol. 2002 Apr 3;39(7):1163-9.</citation>
    <PMID>11923041</PMID>
  </reference>
  <reference>
    <citation>Inoue N, Ishikawa T, Sumita S, Nakagawa T, Kobayashi T, Matsushita K, Matsumoto K, Ohkusu Y, Taima M, Kosuge M, Uchino K, Kimura K, Umemura S. Long-term follow-up of atrioventricular delay optimization in patients with biventricular pacing. Circ J. 2005 Feb;69(2):201-4.</citation>
    <PMID>15671613</PMID>
  </reference>
  <reference>
    <citation>Meisner JS, McQueen DM, Ishida Y, Vetter HO, Bortolotti U, Strom JA, Frater RW, Peskin CS, Yellin EL. Effects of timing of atrial systole on LV filling and mitral valve closure: computer and dog studies. Am J Physiol. 1985 Sep;249(3 Pt 2):H604-19.</citation>
    <PMID>3839979</PMID>
  </reference>
  <reference>
    <citation>Morales MA, Startari U, Panchetti L, Rossi A, Piacenti M. Atrioventricular delay optimization by doppler-derived left ventricular dP/dt improves 6-month outcome of resynchronized patients. Pacing Clin Electrophysiol. 2006 Jun;29(6):564-8.</citation>
    <PMID>16784420</PMID>
  </reference>
  <reference>
    <citation>Steendijk P, Tulner SA, Bax JJ, Oemrawsingh PV, Bleeker GB, van Erven L, Putter H, Verwey HF, van der Wall EE, Schalij MJ. Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure-volume loops. Circulation. 2006 Mar 14;113(10):1295-304. Epub 2006 Mar 6.</citation>
    <PMID>16520415</PMID>
  </reference>
  <reference>
    <citation>Hardt SE, Yazdi SH, Bauer A, Filusch A, Korosoglou G, Hansen A, Bekeredjian R, Ehlermann P, Remppis A, Katus HA, Kuecherer HF. Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapy. Int J Cardiol. 2007 Feb 14;115(3):318-25. Epub 2006 Aug 7.</citation>
    <PMID>16891011</PMID>
  </reference>
  <reference>
    <citation>Tournoux FB, Alabiad C, Fan D, Chen AA, Chaput M, Heist EK, Mela T, Mansour M, Reddy V, Ruskin JN, Picard MH, Singh JP. Echocardiographic measures of acute haemodynamic response after cardiac resynchronization therapy predict long-term clinical outcome. Eur Heart J. 2007 May;28(9):1143-8. Epub 2007 Apr 21.</citation>
    <PMID>17449877</PMID>
  </reference>
  <reference>
    <citation>Vidal B, Sitges M, Marigliano A, Delgado V, Díaz-Infante E, Azqueta M, Tamborero D, Tolosana JM, Berruezo A, Pérez-Villa F, Paré C, Mont L, Brugada J. Optimizing the programation of cardiac resynchronization therapy devices in patients with heart failure and left bundle branch block. Am J Cardiol. 2007 Sep 15;100(6):1002-6. Epub 2007 Jul 5.</citation>
    <PMID>17826387</PMID>
  </reference>
  <reference>
    <citation>Kedia N, Ng K, Apperson-Hansen C, Wang C, Tchou P, Wilkoff BL, Grimm RA. Usefulness of atrioventricular delay optimization using Doppler assessment of mitral inflow in patients undergoing cardiac resynchronization therapy. Am J Cardiol. 2006 Sep 15;98(6):780-5. Epub 2006 Jul 28.</citation>
    <PMID>16950184</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <results_first_submitted>July 27, 2012</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>HF</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>CRT</keyword>
  <keyword>Optimization</keyword>
  <keyword>SmartDelay</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>AV Delay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1060 patients were enrolled. 46 patients were not implanted with a CRT-D: screening failures (27), withdrawn by physician/sponsor (15) or withdrew consent (4). 34 implanted patients were not randomized: screening failures (13), withdrawn by physician/sponsor (14), withdrew consent (4), LTFU (2), death (1), not properly randomized (3)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fixed AV Delay</title>
          <description>Patients programmed to a Fixed nominal AV delay of 120 ms with a sensed AV offset set to 0 and the LV offset set to 0</description>
        </group>
        <group group_id="P2">
          <title>Echo Optimized AV Delay</title>
          <description>Echo optimized AV delay (Iterative Method), LV offset is optional</description>
        </group>
        <group group_id="P3">
          <title>Algorithm Optimized AV Delay</title>
          <description>Algorithm optimized AV delay with sensed and paced AV delay recommendations and LV offset set to 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="323"/>
                <participants group_id="P3" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="282"/>
                <participants group_id="P3" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unavailable or unreadable 6 month LVESV</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fixed AV Delay</title>
          <description>Patients programmed to a Fixed nominal AV delay of 120 ms with a sensed AV offset set to 0 and the LV offset set to 0</description>
        </group>
        <group group_id="B2">
          <title>Echo Optimized AV Delay</title>
          <description>Echo optimized AV delay (Iterative Method), LV offset is optional</description>
        </group>
        <group group_id="B3">
          <title>Algorithm Optimized AV Delay</title>
          <description>Algorithm optimized AV delay with sensed and paced AV delay recommendations and LV offset set to 0</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="325"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="332"/>
            <count group_id="B4" value="980"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="10.6"/>
                    <measurement group_id="B2" value="65.8" spread="11.2"/>
                    <measurement group_id="B3" value="66.1" spread="11.3"/>
                    <measurement group_id="B4" value="66.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="307"/>
                    <measurement group_id="B4" value="912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular End-systolic Volume (LVESV)</title>
        <description>Change in square root of absolute left ventricular end systolic volume from baseline to 6 month follow up</description>
        <time_frame>6 months</time_frame>
        <population>Availability of baseline and 6 month echocardiograms with primary endpoint values (LVESV) among randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed AV Delay</title>
            <description>Patients programmed to a Fixed nominal AV delay of 120 ms with a sensed AV offset set to 0 and the LV offset set to 0</description>
          </group>
          <group group_id="O2">
            <title>Echo Optimized AV Delay</title>
            <description>Echo optimized AV delay (Iterative Method), LV offset is optional</description>
          </group>
          <group group_id="O3">
            <title>Algorithm Optimized AV Delay</title>
            <description>Algorithm optimized AV delay with sensed and paced AV delay recommendations and LV offset set to 0</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-systolic Volume (LVESV)</title>
          <description>Change in square root of absolute left ventricular end systolic volume from baseline to 6 month follow up</description>
          <population>Availability of baseline and 6 month echocardiograms with primary endpoint values (LVESV) among randomized patients</population>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" lower_limit="-41" upper_limit="6"/>
                    <measurement group_id="O2" value="-19" lower_limit="-45" upper_limit="6"/>
                    <measurement group_id="O3" value="-21" lower_limit="-45" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Gate keeping strategy utilized for Type 1 error control described in design paper - negative results observed for initial comparisons - (each at alpha = .05) between fixed and algorithm optimized AV delay and fixed and Echo optimzied AV. Results from both of these comparisons were non-significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.66</p_value>
            <method>ANOVA</method>
            <method_desc>As LVESV values were non normal by Q-Q analysis and Shapiro-Wilk test (p&lt;.05), a square root transform was used. model adjusted for baseline LVESV.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoints Will Include Structural and Functional Measures</title>
        <time_frame>Chronic</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from randomization through the 6-month follow-up visit. Per trial design, serious adverse events were not collected in this trial.</time_frame>
      <desc>Source vocabulary for AE coding was not used in this trial. Serious adverse events were not collected in this trial per trial design.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fixed AV Delay</title>
          <description>Patients programmed to a Fixed nominal AV delay of 120 ms with a sensed AV offset set to 0 and the LV offset set to 0</description>
        </group>
        <group group_id="E2">
          <title>Echo Optimized AV Delay</title>
          <description>Echo optimized AV delay (Iterative Method), LV offset is optional</description>
        </group>
        <group group_id="E3">
          <title>Algorithm Optimized AV Delay</title>
          <description>Algorithm optimized AV delay with sensed and paced AV delay recommendations and LV offset set to 0</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="325"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PG Related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="325"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>RA Lead Related</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="325"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>RV Lead Related</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="325"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="323"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Procedure Related</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="325"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>LV Lead Related</sub_title>
                <counts group_id="E1" events="60" subjects_affected="51" subjects_at_risk="325"/>
                <counts group_id="E2" events="57" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E3" events="39" subjects_affected="36" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cardiovascular Related</sub_title>
                <counts group_id="E1" events="108" subjects_affected="71" subjects_at_risk="325"/>
                <counts group_id="E2" events="116" subjects_affected="77" subjects_at_risk="323"/>
                <counts group_id="E3" events="132" subjects_affected="88" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Death not related to any of the other Adverse Event categories</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiovascular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="325"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Greg Voss, Clinical Director</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>651-581-3068</phone>
      <email>gregory.voss@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

